Search research articles
Contact Us
Filters
Showing results (351-360 of 397) with videos related to
Page
of 40
Sort By:
Journal for Immunotherapy of Cancer
|
June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Yi Liu, Jodi M Carter, Yaohua Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
Breast Cancer Research and Treatment
|
November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
The Journal of Clinical Investigation
|
June 8, 2021
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
Yundong He, Liguo Wang, Ting Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2020
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer
Siddhartha Yadav, Chunling Hu, Steven N Hart, et al.
Nature Communications
|
April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2017
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
Matthew P Goetz, Vera J Suman, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo, Paul H Frankel, Banu K Arun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
M P Goetz, N A Bagegni, G Batist, et al.
Page
of 40
Search research articles
Search
Showing results (351-360 of 397) with videos related to
Sort By:
Page
of 40
Journal for Immunotherapy of Cancer
|
June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Yi Liu, Jodi M Carter, Yaohua Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
Breast Cancer Research and Treatment
|
November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
The Journal of Clinical Investigation
|
June 8, 2021
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
Yundong He, Liguo Wang, Ting Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2020
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer
Siddhartha Yadav, Chunling Hu, Steven N Hart, et al.
Nature Communications
|
April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2017
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
Matthew P Goetz, Vera J Suman, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo, Paul H Frankel, Banu K Arun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
M P Goetz, N A Bagegni, G Batist, et al.
Page
of 40